Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: Zalcitabine has superior activity compared to cidofovir

Kohsuke Nakagawara1,2, Hironori Hayashi1,3, Kumi Kawaji1, Mina Sasano1 and Eiichi N Kodama1

Abstract
Human adenovirus type 19 (HAdV-19) is a major cause of the epidemic keratoconjunctivitis. Outbreaks of keratoconjunctivitis are problematic to human health, especially for infants, the elderly, and immunocompromised individuals. However, the development of anti-HAdV drugs has been hampered by inconvenient screening systems; therefore, development of a simple screening method is highly desirable. In this study, we identified that HAdV-19 can infect a human lymphoid cell line transformed with human T-cell leukemia virus (MT-2 cells). MT-2 cells supported HAdV-19 replication and showed apparent cytopathic effects within five days post-infection. Using a thiazolyl blue tetrazolium bromide (MTT)-based colorimetric assay on MT-2 cells, we were able to detect the anti-HAdV-19 activities of previously reported nucleoside/tide compounds, including (S)-1–(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir), 2’,3’-dideoxycytidine (zalcitabine) and 3’-deoxy-3’-fluorothymidine (trifluridine). Compared with previous methods, this system represents a more simple and rapid method to screen anti-HAdV-19 agents.

Keywords
Adenovirus, screening, antiviral, pandemic, disaster

Introduction
Human adenoviruses (HAdV) cause various mucosal infections, including respiratory infections, gastroenteritis, and hemorrhagic cystitis. While most infections are acute and cause severe symptoms, most patients have a good prognosis. However, HAdV infections can induce severe and lethal disseminated diseases in immunocompromised individuals. Additionally, ocular HAdV infection causes epidemic keratoconjunctivitis (EKC). HAdV type 19 (HAdV-19) is a major etiological agent of EKC, a severe and contagious infection associated with blurred vision and irritation. EKC outbreaks are problematic when they emerge in hospitals, schools, and other communities. A number of compounds, such as cidofovir (CDV), zalcitabine (ddC), and ribavirin (RBV), reportedly show anti-HAdV activity in vitro or in vivo. A newly developed compound, brincidofovir, a promising lipid-linked derivative of CDV, has been used in clinical trials. However, no anti-HAdV agents have been clinically approved.

The anti-HAdV activity of compounds has been examined in vitro using adherent cells, such as A549, HEp-2, and human embryonic lung (HEL) fibroblast cells.

1 Division of Infectious Diseases, International Institute of Disaster Science, Graduate School of Medicine, Tohoku Medical Megabank Organization, Tohoku University, Miyagi, Japan
2 Biochemicals Division, Yamasa Corporation, Choshi, Japan
3 Department of Intelligent Network for Infection Control, Graduate School of Medicine, Tohoku University, Miyagi, Japan

Corresponding author:
Eiichi N Kodama, Division of Infectious Diseases, International Institute of Disaster Science, Graduate School of Medicine, Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo Aoba-ku, Sendai, Miyagi 980-8575, Japan.
Email: kodama515@med.tohoku.ac.jp
These antiviral assays can require considerable effort to change culture media. Additionally, the trypsin treatments, antibiotics, and media can create variation in assay results. In this study, we developed an anti-adenoviral assay using non-adherent cells to avoid these problems. We demonstrated that MT-2 cells, which are a human lymphocytic cell line transformed with human T-cell leukemia virus (HTLV-1), support the infection and propagation of HAdV-19. Cytopathic effects (CPE) of HAdV-19 infection on MT-2 cells were also evaluated by testing the infected cells for viability using a thiazolyl blue tetrazolium bromide (MTT) assay. We tested several classes of nucleoside/tide analogues such as CDV, ddC, RBV, ganciclovir (GCV), and 3'-deoxy-3'-fluorothymidine (FdT) that are known to inhibit HAdV. Except FdT, our MTT assay results agreed with previous reports on the anti-HAdV activities of these compounds. These results suggest that screening HAdV inhibitors using an MTT assay on MT-2 cells may be a useful tool for the development of novel HAdV inhibitors.

Materials and methods

Cell cultures and virus

A human lymphoid cell line, MT-2 (a kind gift from Dr. Shiro Shigeta, Fukushima Medical University, Fukushima, Japan), was grown in RPMI 1640 medium (Sigma-Aldrich Japan, Tokyo, Japan) supplemented with 10% fetal calf serum (FCS; Gibco, Thermo Fisher Scientific, Tokyo, Japan), 2 mM L-glutamine, 100 units/ml of penicillin, and 100 μg/ml of streptomycin (Meiji Seika Pharma Co. Ltd, Tokyo, Japan). A549 cells (procured from the RIKEN BRC through the National BioResource Project of the MEXT/AMED, Japan) were grown in DMEM (Sigma) supplemented with 10% FCS, 2 mM L-glutamine, 100 units/ml of penicillin, and 100 μg/ml of streptomycin. Cells were incubated at 37°C in a humidified atmosphere with 5% CO₂. HAdV-19 (ATCC, Manassas, VA) was propagated in A549 cells and stored at −80°C. Mean titers were calculated and expressed as median tissue culture infectious dose per ml (TCID₅₀/ml).

MTT-based antiviral and cytotoxic assay

To evaluate anti-HAdV activity, the RPMI 1640- or DMEM-based assay medium, for MT-2 or A549 cells, respectively, with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC), ddC, FdT, RBV, and GCV (Sigma-Aldrich Japan), was added in duplicate to wells on flat-bottom 96-well plates. MT-2 cells and A549 cells were mixed with HAdV-19, 2 × 10⁵ cells/ml with 10⁴ TCID₅₀/ml and 1 × 10⁵ cells/ml with 3 × 10³ TCID₅₀/ml, respectively, in plate wells in the presence or absence of various concentrations of the compounds (MOI: 0.035 for MT-2 cells and 0.021 for A549). The plates were incubated for five days. At the end of the incubation period, CPE was determined using the MTT assay, as described previously. Thus, 25 μl of the MTT solution (7.5 mg/ml) in phosphate-buffered saline (Wako, Japan) was added to each well of the plate. Then, the plate was incubated at 37°C for 2 h. After incubation, 150 μl of medium was removed with care in order not to draw cells. To solubilize the formazan crystals and neutralize the viral infectivity, 100 μl of acidified isopropanol (4 ml concentrated HCl per 1 l of isopropanol) containing 10% (v/v) Triton X-100 was added to each well. Formazan crystals were completely solubilized by pipetting up and down, the absorbance at 560 nm of the wells was read by microplate reader (GloMax, Promega, Japan). The 50% antiviral effective concentration (EC₅₀) was defined as the drug concentration that protects 50% of virus-infected cells from virus-induced cell damage and/or death. The cytotoxicity of each compound was measured in parallel using the MTT assay. The 50% cytotoxicity concentration (CC₅₀) was defined as the drug concentration that reduces cell viability by 50%. Data shown represent mean EC₅₀ and CC₅₀ values (±1 standard deviation) derived from the results of two to four independent experiments conducted in duplicate.

Quantitative PCR for detecting viral DNA from HAdV-19

A set of primers synthesized by Echavarria et al. that amplify a 139-bp region of the hexon gene (set II) was used, as previously described. Thermal Cycler Dice Real Time System Lite (Takara Bio, Kusatsu, Japan) was used for DNA amplification.

Results

Cytopathic effects of HAdV-19 infection against MT-2 cells

To examine the infectivity and CPE of HAdV-19, we microscopically observed HAdV-19-infected MT-2 cells. CPE was observed in a dose-dependent manner after five days of HAdV-19 infection at 10², 10³, and 10⁴ TCID₅₀. A 100% CPE was observed at 10³ and 10⁴ TCID₅₀ (Figure 1(c) and (d)). To determine the time course of HAdV-19-induced CPE, we examined the inhibition of formazan formation in MT-2 cells on days 3, 5, and 7 post-infection. The optical density at 560 nm (OD₅₆₀) values decreased in a time-dependent manner.
manner (Figure 1(e)). On day 5, the OD560 values had decreased by approximately 80%, 40%, 20%, and 10% compared with the control, upon infection with HAdV-19 at 10⁴, 10³, 10², and 10⁰ TCID₅₀ per well, respectively (Figure 1(e)). The Z’ factor was 0.94 when the cells were infected with 10³ TCID₅₀ of HAdV-19, indicating robustness for screening. Therefore, we incubated 10³ TCID₅₀ of HAdV-19 with cells for five days prior to the MTT antiviral assay.

Detection of HAdV-19 by qPCR
To confirm HAdV-19 replication in MT-2 cells, we determined the amount of viral DNA in the culture supernatant of infected cells using qPCR methods. MT-2 cells were infected with 10³ TCID₅₀ of HAdV-19 for four or seven days. As shown in Figure 1(f), the amount of detected viral DNA increased in a time-dependent manner. Seven days post-infection, viral DNA increased more than 150 times compared with the initial amount of viral DNA. Thus, HAdV-19 efficiently replicated in MT-2 cells.

Effect of antiviral compounds against HAdV-19
The antiviral activities of test compounds (CDV, ddC, FdT, RBV, and GCV) were evaluated against HAdV-19 using an MTT assay with MT-2 cells (Table 1). FdT and ddC inhibited HAdV-19 replication with EC₅₀ values of 1.8 and 2.6 μM, respectively. The EC₅₀ values of CDV and GCV were comparable at 62 and 60 μM, respectively. In contrast, RBV showed little
antiviral activity against HAdV-19. For comparison, we also evaluated the EC50 and CC50 of the compounds using A549 cells by MTT assay. The results showed a similar tendency. Thus, FdT and ddC exerted more potent activity than CDV and GCV. In our assay, CDV, ddC, and GCV were tolerated by MT-2 cells at a concentration of 100 μM as was the case with A549 cells. CC50 values of FdT and RBV against MT-2 cells (36 and 18 μM, respectively) were similar values to A549 cells (7.6 and 53 μM, respectively).

Discussion

Most HAdV infections are severe but self-limited, even without a specific therapy. However, HAdV infection in immunosuppressed patients can cause life-threatening illnesses. Additionally, ocular HAdV infection is important because it can cause EKC. Despite this, there are no approved anti-HAdV agents.

The development of anti-HAdV agents has been hampered by problematic antiviral assay methods. Plaque assays have been conventionally used for detecting HAdV infectivity and the anti-HAdV activity of compounds. Additionally, qPCR methods for detecting HAdV were developed and have been useful in analyzing HAdV infection, spread or replication, and time dependence. However, plaque assays and qPCR methods are not convenient for large-scale screening of antiviral agents. In contrast, the development of anti-HIV-1 and anticancer drugs has proven that MTT assays are well suited for drug screening. To date, several MTT methods for screening anti-HAdV agents have been developed. However, these assays use adherent cells such as A549, HEp-2, and HEL fibroblast cells, and thus require more than one week to complete and significant labor to change culture medium. In this report, we have demonstrated that HAdV-19, which was a representative pathogen causing EKC, could infect the human lymphoid cell line, MT-2, although the relationships between lymphoid cells and HAdV-19 pathogenesis have not been clarified, yet. Additionally, we established an anti-HAdV screening method with MT-2 cells using an MTT assay. MT-2 cells could be completed in five days without medium exchange. The anti-HAdV activities of compounds measured by the MTT assay on MT-2 cells showed a similar tendency to those on A549 cells. However, it is well known that the anti-HAdV activities of several compounds are serotype- and cell line dependent. Indeed, our method detected an EC50 value of FdT (1.8 μM) that is 10 to 100 times higher than the previously reported EC50 values determined in HAdV-2 and -3-infected Fogh and Lund (FL) cells, which were originally obtained from normal amnion but were subsequently believed to be HeLa cell contamination. Thus, the discrepancies between the reported EC50 values for FdT might result from the different HAdV serotypes and/or cell lines used in each study. These findings suggest that an MTT assay with MT-2 cells could be a useful tool for high-throughput screening of anti-HAdV agents. This simple, rapid, and convenient method can accelerate and enhance the development of anti-HAdV agents.

Acknowledgments

We are grateful to Emiko Usui for editorial help. We thank Lara Wilson, PhD, and Gillian Campbell, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this article.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: K.N. is an employee of Yamasa Corporation. The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by research grants

Table 1. Antiviral and cytotoxic effects of tested compounds against HAdV-19 determined by MTT assay.

| Compounds | MT-2      | A549      | MT-2 | A549 | SI  |
|-----------|-----------|-----------|------|------|-----|
|            | EC50 (µM) | CC50 (µM) |      |      |     |
| CDV       | 62±26     | 4.2±1.1   | >100 | >1.6 | >24 |
| ddC       | 2.6±0.4   | 0.35±0.04 | >100 | >38  | >286|
| FdT       | 1.8±0.2   | 0.03±0.01 | 36±5 | 7.6±4.2 | 20 |
| RBV       | >18       | >53       | 18±1 | 53±21| NA  |
| GCV       | 60±7      | 54±27     | >100 | >1.7 | >1.9|

Note: All assays to determine EC50 were conducted two to four times independently. The results are shown as means ± standard deviation. The selectivity index (SI) is the ratio of CC50 and EC50 values.

CDV: cidovir; ddC: zalcitabine; FdT: 3’-deoxy-3’-fluorothymidine; RBV: ribavirin; GCV: ganciclovir.
from the Japan Society of the Promotion for Science (JSPS No. 16H05346) and by the Joint Usage/Research Center, Research Center for Zoonosis Control, Hokkaido University.

ORCID iD
Eiichi N Kodama
https://orcid.org/0000-0002-6622-2752

References
1. Ghebremedhin B. Human adenovirus: viral pathogen with increasing importance. Eur J Microbiol Immunol (Bp) 2014; 4: 26–33.
2. Lenaerts L, De Clercq E and Naesens L. Clinical features and treatment of adenovirus infections. Rev Med Virol 2008; 18: 357–374.
3. Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191: 396–399.
4. Stock R, Harste G, Madisch I, et al. A rapid quantitative PCR-based assay for testing antiviral agents against human adenoviruses demonstrates type specific differences in ribavirin activity. Antiviral Res 2006; 72: 34–41.
5. Kaneko H, Kato K, Mori S, et al. Antiviral activity of NMSO3 against adenovirus in vitro. Antiviral Res 2001; 52: 281–288.
6. Naesens L, Lenaerts L, Andrei G, et al. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob Agents Chemother 2005; 49: 1010–1016.
7. Trousdale MD, Goldschmidt PL and Nóbrega R. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea 1994; 13: 435.
8. Gordon Y, Romanowski E, Araullo-Cruz T, et al. Inhibitory effect of (S)-HPMPC,(S)-HPMPA, and 2′,3′-n-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991; 16: 11–16.
9. Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther (Lond) 2005; 10: 225–229.
10. Mentel R, Kinder M, Wegner U, et al. Inhibitory activity of 3′-fluoro-2′-deoxymethylidine and related nucleoside analogues against adenoviruses in vitro1. Antiviral Res 1997; 34: 113–119.
11. Kodama E, Shigeta S, Suzuki T, et al. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antiviral Res 1996; 31: 159–164.
12. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20: 309–321.
13. Echavarria M, Forman M, Ticehurst J, et al. PCR method for detection of adenovirus in urine of healthy and human immunodeficiency virus-infected individuals. J Clin Microbiol 1998; 36: 3323–3326.
14. Romanowski EG, Yates KA and Gordon YJ. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections. Invest Ophthalmol Vis Sci 2009; 50: 5295–5299.
15. Boniñas V and Schlesinger R. Nutritional requirements for plaque production by adenovirus. In: Federation proceedings. Bethesda, MD: Federation Proc Amer Soc Exp Biol, 1959, p.560–590.
16. Kjellén L. A study of adenovirus-host cell system by the plaque technique. Virology 1961; 14: 234–239.
17. Ghosh AK, Ramu Sridhar P, Kumaragurubaran N, et al. Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance. ChemMedChem: Chemistry Enabling Drug Discovery 2006; 1: 939–950.
18. Maeda K, Desai DV, Aoki M, et al. Delayed emergence of HIV-1 variants resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001. Antivir Ther (Lond) 2014; 19: 179–189.
19. Takamatsu Y, Das D, Kohgo S, et al. The high genetic barrier of EFdA/MK-8591 stems from strong interactions with the active site of drug-resistant HIV-1 reverse transcriptase. Cell Chem Biol 2018; 25: 1268–1278. e3.
20. Hattori S-I, Hayashi H, Bulut H, et al. Halogen bond interactions of novel HIV-1 protease inhibitors (PI) (GRL-001-15 and GRL-003-15) with the flap of protease are critical for their potent activity against wild-type HIV-1 and multi-PI-resistant variants. Antimicrob Agents Chemother 2019; 63: e02635–18.
21. Smith C, Craft D, Shromoto R, et al. Alternative cell line for virus isolation. J Clin Microbiol 1986; 24: 265–268.
22. Oghura Y, Yoshinouchi M, Kudo T, et al. Human papillomavirus type 18 DNA in so-called HEP-2, KB and FL cells – further evidence that these cells are HEpA cell derivatives. Cellular and Molecular Biology (Noisy-le-Grand, France.) 1993; 39: 463–467.